ADME/DDI/PK

Remember: “One size fits nothing in ADMET/PK”

• when to use recombinant versus microsomal CYP inhibition?

• when should you use a cassette versus discrete PK approach?

• what exactly is PK/PD in your project?

• can you use the rat alone to predict human PK?

No matter if your project is in early drug discovery, lead optimization or already in candidate profiling during pre-clinical development, CapEval Pharma can help to find the right assay conditions to improve, fine-tune and/or fully characterize drug-likeness, ADME, DDI potential and cross-species PK including human PK and dose prediction. 

We can help you with:

• Evaluation of in silico data and physicochemical properties

• Proposal for early high throughput ADME assays

• Detailed SOPs and technical help for all advanced ADME assays

• Metabolite identification incl. CYP or other enzyme mapping

• Transporter evaluation (substrate and inhibition format)

• Advice how to approach new 2012 FDA guidance for DDI

• Metabolites in safety testing (MIST FDA Guidance)

• Toxicophores and reactive intermediate assays

• New early safety assays (e.g. HCS screening, Greenscreen)

• CYP induction studies

• Design and conduct of PK experiments (in house or CRO) for rodents, rabbit, dog, minipig, NHP

• Target-specific PK/PD approaches

• Allometry, human PK and dose prediction

• Radiolabeled in vitro met ID in combination with rodent/non-rodent mass balance/metabolite profiling, QWBA